Abstract
Background During the COVID-19 pandemic, wastewater-based surveillance gained great international interest as an additional tool to monitor SARS-CoV-2. In autumn 2021, the Norwegian Institute of Public Health decided to pilot a national wastewater surveillance (WS) system for SARS-CoV-2 and its variants between June 2022 and March 2023. We evaluated the system to assess if it met its objectives and its attribute-based performance.
Methods We adapted the available guidelines for evaluation of surveillance systems. The evaluation was carried out as a descriptive analysis and consisted of the following three steps: (i) description of the WS system, (ii) identification of users and stakeholders, and (iii) analysis of the system’s attributes and performance including sensitivity, specificity, timeliness, usefulness, representativeness, simplicity, flexibility, stability, and communication. Cross-correlation analysis was performed to assess the system’s ability to provide early warning signal of new wave of infections.
Results The pilot WS system was a national surveillance system using existing wastewater infrastructures from the largest Norwegian municipalities. We found that the system was sensitive, timely, useful, representative, simple, flexible, acceptable, and stable to follow the general trend of infection. Preliminary results indicate that the system could provide an early signal of changes in variant distribution. However, challenges may arise with: (i) specificity due to temporary fluctuations of RNA levels in wastewater, (ii) representativeness when downscaling, and (iii) flexibility and acceptability when upscaling the system due to limited resources and/or capacity.
Conclusions Our results showed that the pilot WS system met most of its surveillance objectives. The system was able to provide an early warning signal of 1-2 weeks, and the system was useful to monitor infections at population level and complement routine surveillance when individual testing activity was low. However, temporary fluctuations of WS values need to be carefully interpreted. To improve quality and efficiency, we recommend to standardise and validate methods for assessing trends of new waves of infection and variants, evaluate the WS system using a longer operational period particularly for new variants, and conduct prevalence studies in the population to calibrate the system and improve data interpretation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The pilot project has been approved and financed by NIPH. One of the co-authors was financially supported by the European Programme for Public Health Microbiology Training (EUPHEM), ECDC. The funder had no role in study design, data collection and interpretation, or the decision to submit the work for publication. There was no additional funding for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Regional Committee for medical and healthcare research ethics (REK 454077) based on the Norwegian Health Research Act
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Typo in numbering figures, replacing 'Figure 5' with 'Figure 3'. Updating subject area under 'epidemiology'.
Data Availability
The dataset analysed in the study contains individual-level data from various central health registries or laboratory databases. Only fully anonymized data (i.e., data that are neither directly nor potentially indirectly identifiable) are permitted to be shared publicly. Therefore, legal restrictions prevent the researchers from publicly sharing the dataset used in the study. However, external researchers are freely able to request access to data as per normal procedure for conducting health research in line with national and European regulations concerning data protection.
Abbreviations
- WS
- Wastewater surveillance
- MSIS
- The Norwegian surveillance system for communicable diseases
- NIPH
- Norwegian Institute of Public Health
- ECDC
- European Centre for Disease Prevention and Control
- CDC
- U.S. Centers for Disease Control and Prevention
- PCR
- Polymerase Chain Reaction
- RT-PCR
- Reverse Transcription Polymerase Chain Reaction
- RT-qPCR
- Quantitative Reverse Transcription Polymerase Chain Reaction
- Beredt C19
- Emergency Preparedness Register for COVID-19
- ICU
- Intensive Care Unit
- PMMoV
- Pepper Mild Mottle Virus
- VOC
- Variant of Concern
- EU
- European Union
- EEA
- European Economic Area
